臺北醫學大學生醫器材研究中心

Pharmacology, Toxicology and Pharmaceutical Science

1. Malignant Neoplasm 100%
2. Nanoparticle 79%
3. Chitosan 55%
4. Neoplasm 55%
5. Disease 52%
6. Cohort Study 50%
7. Mouse 47%
8. Randomized Controlled Trial 44%
9. Chronic Kidney Failure 44%
10. Reactive Oxygen Metabolite 40%
11. Inflammation 40%
12. Chronic Obstructive Lung Disease 37%
13. Gelatin 32%
14. Lung Cancer 30%
15. Hyaluronic Acid 30%
16. Fucoidan 29%
17. Hemodialysis 29%
18. Sleep Disordered Breathing 29%
19. Vaccination Policy 26%
20. Epidermal Growth Factor Receptor 26%
21. Endothelin 1 25%
22. Antioxidant 25%
23. Cytotoxicity 24%
24. Doxorubicin 23%
25. Combination Therapy 23%
26. Breast Cancer 21%
27. Infection 21%
28. Cell Viability 21%
29. Liposome 19%
30. Diabetes Mellitus 19%
31. Wound Healing 18%
32. Antiinfective Agent 18%
33. Chemotherapy 17%
34. Mitogen Activated Protein Kinase 17%
35. Cardiovascular Disease 17%
36. Symptom 17%
37. Adverse Event 17%
38. Growth Factor 17%
39. Angiotensin II 17%
40. Drug Delivery System 16%
41. Lipopolysaccharide 16%
42. Bipolar Disorder 16%
43. Injury 15%
44. Alginic Acid 15%
45. Tumor Necrosis Factor 15%
46. Tumor Growth 15%
47. Nitric Oxide 15%
48. Therapeutic Effect 15%
49. Rat Model 14%
50. Asthma 14%
51. Biocompatibility 14%
52. Cytokine 14%
53. Calcium Phosphate 14%
54. Nanocarrier 14%
55. Epigallocatechin Gallate 14%
56. Hydroxyapatite 12%
57. Prevalence 12%
58. Leporidae 12%
59. Survival Rate 12%
60. Acute Heart Infarction 12%
61. End Stage Renal Disease 12%
62. Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 12%
63. Polysaccharide 12%
64. Heart Infarction 12%
65. Wound 11%
66. Atrial Fibrillation 11%
67. Case-Control Study 11%
68. Parkinson's Disease 11%
69. Western Blot 11%
70. Biological Marker 11%
71. Mesoporous Silica Nanoparticle 11%
72. Implant 11%
73. Fibrinogen 11%
74. Fibrosis 11%
75. Non Small Cell Lung Cancer 11%
76. Drug Release 11%
77. Nanomaterial 11%
78. Lung Adenocarcinoma 10%
79. Liver Cell Carcinoma 10%
80. Mouse Model 10%
81. Infectious Agent 10%
82. Alkaline Phosphatase 10%
83. Urotensin II 10%
84. Sleep Disorder 10%
85. Polyglutamic Acid 10%
86. Clinical Trial 10%
87. Dry Eye 10%
88. Receptor 10%
89. Nuclear Factor 10%
90. Kidney Disease 10%
91. Thrombosis 10%
92. Placebo 10%
93. Resveratrol 10%
94. Cisplatin 9%
95. Non Insulin Dependent Diabetes Mellitus 9%
96. All Cause Mortality 9%
97. Cyclooxygenase 2 9%
98. Colon Cancer 9%
99. Side Effect 9%
100. Antihypertensive Agent 9%

Medicine and Dentistry

1. In Vitro 64%
2. Meta-Analysis 57%
3. Platelet 49%
4. Randomized Controlled Trial 47%
5. Implant 46%
6. Cohort Analysis 43%
7. Systematic Review 40%
8. Malignant Neoplasm 39%
9. Chronic Kidney Disease 35%
10. Apoplexy 35%
11. Platelet Lysate 34%
12. Medicine 34%
13. Isotopes of Calcium 30%
14. Chronic Obstructive Pulmonary Disease 29%
15. Restylane 29%
16. Disease 28%
17. Hazard Ratio 25%
18. Diabetes Mellitus 22%
19. Symptom 22%
20. Influenza Vaccination 22%
21. Fibroblast 22%
22. Neoplasm 22%
23. Oral Implants 21%
24. Obstructive Sleep Apnea 20%
25. Lung Cancer 19%
26. Cancer Cell 19%
27. Osseointegration 19%
28. Injury 19%
29. Growth Factor 18%
30. Chondrocyte 18%
31. Odds Ratio 17%
32. Hemodialysis 17%
33. Rehabilitation Engineering 17%
34. COVID-19 16%
35. Cell Therapy 16%
36. Thrombocyte Concentrate 16%
37. Endothelial Cell 16%
38. Surgery 16%
39. Blood Pressure 15%
40. Health Care Cost 15%
41. Infection 15%
42. Mesenchymal Stem Cell 15%
43. Breast Cancer 15%
44. Osteolysis 15%
45. Computer Assisted Tomography 15%
46. Programmed Cell Death 14%
47. Gelatin 14%
48. Knee 14%
49. Nanoparticle 14%
50. Epidermal Growth Factor Receptor 14%
51. Spinal Cord Injury 14%
52. Dental Implant 14%
53. Bone Regeneration 14%
54. Cell Proliferation 13%
55. Functional Electrical Stimulation 13%
56. Bone Graft 13%
57. Prevalence 13%
58. Drug Therapy 13%
59. Ossification 13%
60. Hydroxylapatite 13%
61. Platelet-Rich Fibrin 13%
62. Biological Marker 13%
63. Signal Transduction 13%
64. Gene Expression 12%
65. Metastatic Carcinoma 12%
66. Osteoarthritis 12%
67. Quality of Life 12%
68. Knee Osteoarthritis 12%
69. Osteoblast 12%
70. Adverse Event 12%
71. Cardiovascular Disease 12%
72. Electrostimulation 12%
73. Diabetes 12%
74. Clinical Trial 12%
75. Traumatic Brain Injury 12%
76. Urination 11%
77. Diagnosis 11%
78. Pulse Rate 11%
79. Asthma 11%
80. Acute Heart Infarction 11%
81. Cardiovascular System 11%
82. Upper Limb 11%
83. Parkinson's Disease 11%
84. Tumor Progression 11%
85. Combination Therapy 11%
86. Nephropathy 11%
87. Case-Control Study 10%
88. Calcium Sulfate 10%
89. Angiogenesis 10%
90. Particular Matter 2.5 10%
91. Atrial Fibrillation 10%
92. Magnetic Resonance Imaging 10%
93. Dental Pulp Stem Cell 10%
94. Bone Defect 10%
95. Heart Failure 10%
96. Tumor Necrosis Factor 10%
97. Vascular Endothelial Cell 10%
98. Cell Viability 10%
99. Edentulism 10%
100. Heart Rate Variability 10%